Earlier, today during the after-market trading session, Motus GI Holdings, Inc. (NASDAQ: MOTS) stock dropped approximately 1.82%. Stock closed on Monday 28th June, 2021 at $1.10 and the stock has noticed a fall in value of -0.01, a -0.90 percent loss. However, no news has been published by the company to point for the recent MOTS stock activity.
What Has Been Happening With Motus GI Holdings, Inc. (NASDAQ: MOTS)?
Motus, is medical technology company that aims to provide treatment for colorectal cancer and other diseases related to rectum and colon. The company is motivated for the development and commercialization of Pure-Ve system to improve colonoscopy experience and timely detection of the disease. MOTS, is also intended to provide a cost efficient and effective patient experience. On a bright side, MOTS has made certain advancements early on during the month.
As of June 3rd,2021 MOTS announces its publication of pure-ve system in peer-reviewed journal BMC gastroenterology. MOTS believes, that evaluation of data from REDUCE (reliable endoscopic diagnosis utilizing cleansing enhancement) study could positively impact Pure-Ve system against bowel preparation quality.
Moreover, during the mid-June, MOTS announced its first patient enrollment in the European Union feasibility study of Pure-Ve system as a New method for bowel cleansing in patients with a history of poor bowel preparation.
Lastly, on Thursday, June 24, 2021, Motus GI appoints experienced financial biotech executive,Sojna Nelson, to its board of directors, as a chair of audit committee, to benefit from her twenty-five years’ experience of financial and operational leadership expertise in biotechnology, diagnostics, and biopharmaceuticals market.
What To Expect From MTOS Stock?
MOTS stock has potential to grow amid its recent advancement in Pure-Ve systems. The stock might break its strong resistance to rebound at its early year rate.